Edwards Lifesciences (India) Profile
Key Indicators
- Authorised Capital ₹ 18.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 18.40 Cr
as on 16-11-2024
- Company Age 28 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 28.59%
(FY 2023)
- Profit -11.95%
(FY 2023)
- Ebitda -0.98%
(FY 2023)
- Net Worth 12.20%
(FY 2023)
- Total Assets -12.35%
(FY 2023)
About Edwards Lifesciences (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 18.50 Cr and a paid-up capital of Rs 18.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Edwards Lifesciences (India) Private Limited India is Harsh Mishra as COMPANY SECRETARY. Parameswaran Nair, Andrew Dahl, Sudheer Mirajkar, and One other member serve as directors at the Company.
- CIN/LLPIN
U33110MH1996PTC145849
- Company No.
145849
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 1996
- Date of AGM
06 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Edwards Lifesciences (India)?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parameswaran Nair  | Managing Director | Current | |
Harsh Mishra  | Company Secretary | 19-Mar-2018 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Andrew Dahl  | Director | 27-Jun-2024 | Current |
| Sudheer Mirajkar | Whole-Time Director | 27-Jun-2024 | Current |
Daniel Lippis  | Director | 27-Jun-2024 | Current |
Financial Performance and Corporate Structure Insights of Edwards Lifesciences (India).
Edwards Lifesciences (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.59% increase. The company also saw a substantial fall in profitability, with a 11.95% decrease in profit. The company's net worth Soared by an impressive increase of 12.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edwards Lifesciences (India)?
In 2023, Edwards Lifesciences (India) had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Edwards Lifesciences (India)?
Unlock and access historical data on people associated with Edwards Lifesciences (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Edwards Lifesciences (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Edwards Lifesciences (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
